© 2026 Sinochem Nanjing Corporation,
All Right Reserved
In the early days of radiographic imaging, contrast agents brought as many risks as they did benefits. Early products relied on high-osmolar compounds that patients struggled to tolerate, causing discomfort or even serious side effects. The search for safer, reliable agents led researchers to look for substances that balanced solubility and radiodensity with a forgiving safety profile. As the 1980s drew closer, a team of chemists pushed iodine chemistry forward, building large, nonionic molecules that carried less risk of reaction. Iopromide emerged from years of this trial and error—after plenty of setbacks, revised molecules and patient studies. Fast-forward a few decades, and iopromide took over as one of the default choices in CT and angiographic diagnostics. Its path tells the story of medical chemistry adjusting to meet clinical realities and growing public demand for safer imaging solutions.
Manufacturers designed iopromide as a low-osmolar, nonionic iodinated contrast medium. The molecule holds together through a tri-iodobenzene ring structure, substituted with hydrophilic amide side chains and additional hydroxyl groups, increasing its water solubility. Modern presentations come as ready-to-use solutions, typically measured by iodine concentration per milliliter—ranging from 150 mg I/mL to as high as 370 mg I/mL for arterial applications. This plug-and-play utility made life easier in imaging suites, cutting down mixing steps and reducing batch-to-batch variability. The packaging, with tamper-proof closures and clear expiry labeling, fits into tight quality chains. A scan using iopromide often supports critical decisions—coronary blockages, brain vessel leaks, or even cancer staging—without provoking undue symptoms in patients who already have plenty to worry about.
Iopromide appears as a clear, colorless to pale yellow solution. The molecular formula, C18H24I3N3O8, packs three iodine atoms per molecule, contributing to strong X-ray absorption across a range of imaging techniques. This chemical dissolves comfortably in water and maintains stability under routine temperature ranges found in hospitals. Its viscosity remains modest even at high concentrations, and interventions against crystallization allow for reliable storage on clinic shelves. The pH is tailored around 7.0, in line with blood, preventing irritation that was so common with older, acidic options. Stat sheets peg its osmolality lower than first-generation agents—another critical point that often goes unappreciated until a patient develops symptoms from hypertonic solutions. The chemistry behind iopromide strikes a balance: strong contrast effect without tipping the body’s biochemistry off balance.
Iopromide comes standardized, routinely carrying designations like 300 mg I/mL or 370 mg I/mL as direct indicators of iodine content. Labels do not just include volume and strength; lot numbers, storage instructions, expiry and barcodes keep quality control watertight. Many vials sport a flip-off cap with tamper evidence, minimizing risks in busy diagnostic settings. As a clear solution, visual checks for debris or color changes serve as daily safety nets, backed by manufacturer guarantees and pharmacopoeia specs. The packaging meets international shipping and storage guidelines, maintaining chemical integrity from the plant to the hospital shelf.
Producing iopromide on an industrial scale does not happen casually. Key starting materials include substituted acetanilide and iodinating agents, evolving into multi-step reactions that install iodine into the aromatic ring while protecting vulnerable positions. Careful monitoring throughout saponification, hydrolysis, and purification steps ensures that no reactive contaminants remain. Automation and in-process analytics allow chemists to batch hundreds of liters without sacrificing control—yielding a production environment where every vial outside the spec range gets flagged and held back. After final filtration and sterile bottling, manufacturers double-check identity and strength using chromatographic and spectroscopic techniques. No shortcutting on purification steps means every dose stacks up in performance and safety.
Some folks working in radiology chemistry take pride in the molecular gymnastics behind iopromide. Developers introduce acetyl groups and fine-tune amide chains to boost solubility. During core synthesis steps, they use mild iodination to prevent excessive substitution—avoiding toxic by-products. Hydrolysis trims unneeded moieties without opening the molecule to oxidation or loss of function. Like neighboring contrasts, iopromide’s modifications respond to lessons from earlier compounds. Med chemists swapped out toxic groups, improving safety margins for patients with kidney issues or delicate immune systems. Those structure tweaks led to a molecule resilient enough for routine clinical cycling, but flexible enough to permit future generations of derivatives with enhanced performance.
Iopromide goes by several titles in clinical practice and the chemical marketplace. Ultravist is the global trade name widely recognized by radiology departments across continents. Chemically, it answers to precise descriptors like “1-N,3-N-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(methoxyacetyl)amino]-N-methylisophthalamide” or shorter forms in scientific literature. European and U.S. pharmacopoeias rhyme off catalog numbers and synonyms, keeping procurement and regulation tidy.
Any hospital stocking iopromide fits its workflow into well-worn protocols crafted around patient safety. Trained staff review allergy histories and check for prior reactions to contrast agents. Nurses flush IV lines before and after use, avoid mixing with incompatible meds, and double up on hydration status for older or renal-impaired patients. Near-instant access to emergency equipment and anaphylaxis kits gets reaffirmed at shift start. Regulatory authorities—FDA, EMA, and local drug agencies—monitor adverse event logs and revise usage guidelines in step with real-world feedback. Audits and batch recalls do not get lost in bureaucracy; they tighten standards year after year. Each manufacturer builds continuous monitoring into the supply chain. Good Manufacturing Practice (GMP) inspections enforce cleanliness, documentation, and parametric control during production. At patient bedsides, those efforts translate to real trust: the comfort of knowing every scan has the best chance of going smoothly.
Radiologists depend on iopromide for a wide set of diagnostic scans. In computed tomography, its rapid vascular distribution and renal clearance highlight organs, blood vessels, and tumors with crisp definition. Cardiology teams reach for iopromide during coronary angiograms and cardiac CTs to pinpoint blockages or plan interventions. Neurology employs the compound for cerebral angiography, evaluating strokes and aneurysms. Urology uses it for excretory urography, highlighting kidneys, ureters, and bladders. Its nonionic, low-osmolar nature makes it the preferred pick for pediatric scans and fragile patients. Emergency departments trust it for quick, clear images when every second matters. Outpatient imaging clinics build repeat business around iopromide’s reputation for reliable, complication-free scans.
Academic labs and pharma development units never stop tinkering with the iopromide backbone. Teams investigate ways to further decrease osmolality or nudge the molecule toward target tissues. Research stretches into using iopromide as a base for dual-modality imaging, blending radiographic and optical techniques. Early studies look at adding bioactive groups for molecular imaging of tumors—trying to move from showing anatomy to suggesting function or pathology. Universities collaborate with industrial partners to push for higher purity, faster clearance, and environmentally friendly synthesis. AI-powered image analysis trains on iopromide-enhanced scans, deepening diagnostic accuracy. Journals never lack fresh papers on tweaking injection protocols for best visualization, minimizing contrast-induced nephropathy, or refining guidelines for the tiniest and most vulnerable patients.
No clinical tool escapes the microscope of safety science. Slight risks of nephrotoxicity draw scrutiny—especially as older populations and diabetic patients use more imaging. Researchers analyze serum creatinine spikes and chase down the root causes of contrast-induced acute kidney injury. Meta-analyses sweep through thousands of case studies, distilling which factors—dosage, hydration, comorbidities—matter most. New animal and cell-culture studies drill down into iopromide’s metabolism and excretion. Findings lead to sharper dosing protocols, pre-scan hydration regimens, and post-scan monitoring that flag trouble early. Big data from hospital systems feeds into guidelines, showing that careful patient selection plus protocol checks push severe adverse events down to rare exceptions. Regulatory updates and clinical guidelines respond in real-time, reflecting the expanding picture from bench to bedside.
Talks around the future of iopromide land on a few hot topics. Some biotech startups eye biodegradable contrast agents that break down even faster after imaging, reducing the load on kidneys and the environment. Major manufacturers invest in greener, more sustainable production processes, lowering chemical waste from synthesis. Integration with AI-driven workflow means radiologists get more out of each scan—maybe even predicting reactions in at-risk populations. Other teams explore how minor molecular tweaks can add selectivity for tumorous tissue or deliver drugs alongside iodine. As diagnostic imaging pushes into low-resource settings, developers ask how to keep cost and handling simple without surrendering safety. Collective experience among chemists, doctors, and manufacturers keeps refining the substance. The arc bends toward smarter, safer, and more versatile contrast options for the next generation of medical diagnostics.
Sitting in a hospital waiting room, you notice the quiet tension before a scan. The nurse calls a name, a patient walks down the hall for a CT scan. Few people know about the liquid that can turn routine imaging into life-saving diagnostic tools. Iopromide does that job, bringing hidden details into view, giving doctors a better shot at coming up with clear answers.
Doctors trust iopromide as a contrast agent in CT scans and other radiological exams. This clear solution, injected into the bloodstream, has earned its place in hospitals because it improves the quality of images. Iopromide’s molecular structure contains iodine, which stands out on X-rays by absorbing more of the radiation. When scanning the blood vessels, heart, brain, or organs like the liver and kidneys, this agent lets doctors spot blockages, tumors, or injuries that could go unnoticed without it.
I have witnessed firsthand how much difference this makes. Without contrast, a scan often looks like a blurry grayscale. With iopromide, sharp patterns emerge. An oncologist can find a tiny tumor sooner. A trauma doctor picks up on internal bleeding that plain scans would miss. Earlier detection changes everything: treatments start sooner, outcomes improve, and patients’ stories take a new turn.
Every medical tool has trade-offs. For most patients, iopromide is safe and out of the body in a day or two. People with healthy kidneys rarely notice anything. Still, the story shifts for those with kidney disease or a heavy load of other health problems. Contrast-induced nephropathy—the risk of kidney damage—remains a real concern.
Doctors and nurses don’t just inject and hope for the best. They run kidney function tests before using iopromide, flag patients at higher risk, and hydrate them to flush out the contrast. Alternatives like MRI or ultrasound without contrast stay on the table for those who can’t take the risk.
In recent years, more research has tackled ways to reduce risk. Lower doses help. Updated protocols and increased awareness have pushed hospitals to build careful screening processes. Some centers have piloted electronic alerts in the medical record that flag vulnerable patients before a scan goes forward. These steps show how a blend of technology and basic caution can limit harm.
Education plays a role too. Clear conversations with patients matter—taking the mystery out of what’s in the IV and why it’s used. Sharing the facts about iopromide’s role can replace fear with trust, making the whole process less intimidating.
Iopromide brings precision to modern diagnosis. It sharpens the view, helps unravel medical puzzles, and saves both time and lives. Risk factors haven’t vanished but new guidelines, careful screening, and a growing culture of patient safety keep shifting the odds in the right direction. Hospitals with experienced teams and clear procedures hold the blueprint for better imaging and better results across the board.
Doctors use iopromide to help highlight organs and blood vessels during X-rays or CT scans. Patients often focus on the benefits, but what happens after the scan can make all the difference. Side effects might seem rare, yet they cause real worry for many people getting imaging tests. A close family member of mine once went for a routine angiogram and came home red-faced, itching, and anxious. It turned out to be a reaction to the contrast dye, iopromide. The story stuck with me and changed how I think about so-called “routine” meds.
Most people sail through a scan without a hitch. A research review published in the Journal of Radiology reports that mild side effects show up in up to 3% of patients. Nausea, vomiting, headache, and a warm flush spread across the body top this list. Usually, these sensations fade quickly. Some folks feel a metallic taste or might start sneezing and coughing. Younger children may cry or show agitation out of the blue.
People with a sensitive immune system or allergies face more risk. Sneezing, runny nose, itchy skin, and rash are signs to watch for. In rare cases, swelling around the face or trouble swallowing can happen. Iopromide doesn’t mix well with some asthma medications, raising the risk of wheezing or breathing trouble.
Most reactions stay mild, but life always likes a curveball. Some hospital emergency rooms tell stories about patients who go into shock or have trouble breathing minutes after injection. These severe allergic-type reactions show up in about 1 out of every 10,000 patients, according to the World Health Organization. Fast treatment saves lives, but these cases leave a lasting impression.
Kidney problems also need a spotlight. Patients with diabetes or weak kidneys face the highest risk for something called contrast-induced nephropathy. Blood test numbers can slip outside the healthy range within a day or two after the scan. This can spell serious trouble for older adults or those with a long history of kidney issues. The FDA has called for extra caution when treating these groups.
Screening questions matter. I always encourage friends to share their allergy history and every medication they take, even vitamins. Drinking plenty of water helps flush the contrast out. Doctors often give IV fluids in the hospital to protect at-risk patients. If someone has reacted to contrast before, medications like steroids or antihistamines might go in before the scan starts.
Hospitals with strict protocols want staff to spot the warning signs early. I’ve worked with teams where staff must stay close-by after the injection, ready with an EpiPen and emergency supplies. This extra caution can make a big difference in keeping patients safe.
Iopromide’s benefits matter, but side effects stack up in real life. Patients deserve open conversation about the risks, honest answers to tough questions, and a plan that puts their safety front and center. My experience—guided by stories from patients and respected doctors—tells me that nothing replaces smart, careful teamwork when it comes to medical imaging.
Hospitals work with all sorts of contrast agents, but iopromide stands out because of its trusted track record in helping doctors see what’s happening inside blood vessels and organs. Every time I watch a technologist fill the syringe, it hits me that this is a moment loaded with expectation—for doctors, patients, and anxious families.
Iopromide comes into play usually during a CT scan or angiogram. No pills, no inhalers. Medical staff inject it, mostly through a vein, and the patient starts early on a journey where every minute counts. Unlike chasing complex protocols, this injection feels matter-of-fact—draw up the right dose, insert an IV line, and push the contrast at the right pace.
Experience on hospital floors quickly shows how thorough preparation shapes outcomes. At one end of the scale, technologists double-check the patient’s history—things like kidney problems, allergies, or thyroid issues. People underestimate how many questions need answers before the tiniest drop of contrast enters a vein. The reality is, complications like allergic reactions, though rare, create stressful scenes for everyone in the room. I have listened to colleagues talk patients through their nerves or explain why they need to drink more fluids before and after the scan. Staying hydrated helps flush the contrast from the body and can lower risk for kidneys that aren’t working at their best.
Doctors choose the dose and method based on weight, age, and clinical need. Children, elderly patients, and folks with health risks need close watching. Over the years, our team started using more automated injectors for larger tests—machines that deliver a precise, steady flow and cut down human error. These tools bring peace of mind, but no tech replaces a sharp nurse watching for trouble signs like itching, hives, or sudden shortness of breath.
The pressure to keep procedures safe never eases up. Training programs matter here; laboratories that offer hands-on practice with mock injections give staff the confidence to act fast if something goes sideways. Guidelines have grown clearer: using the lowest dose possible, checking in on kidney function, and stopping certain medications if needed. These aren’t abstract regulations—they echo in every phone call and pre-scan checklist.
I’ve seen firsthand how the culture of clear communication between radiologists, nurses, and patients saves time and anxiety. Honest answers, not jargon, build trust. If something feels off mid-injection, there are protocol sheets within reach, but it’s the veteran nurse’s eye and quick thinking that make the real difference. Hospitals learn from each close call. Departments now call patients a day ahead to review their records or ask about prior contrast studies. Sometimes, it feels like half the work is double-checking, but people expect safe, predictable care, not surprises.
Lower doses, better equipment, and well-trained teams all contribute to smooth administration. Outpatient centers have started scheduling longer bookings for at-risk cases, so staff aren’t forced to rush. Shared experience among colleagues helps too—a text exchange about a new protocol or a story from another hospital can spark better habits fast.
Ultimately, delivering iopromide isn’t only about accuracy with a syringe but about treating the patient whole, anticipating concerns, and learning from every single scan. Real improvement comes from connecting preparation, observation, and honest teamwork.
Iopromide, a commonly used contrast agent in CT scans and angiography, finds its place in hospitals because it helps doctors see what’s going on inside our bodies. Still, few folks realize not everyone can safely receive this type of contrast dye. Choosing to inject anything into someone’s vein isn’t a small decision—real patients, real risks. That’s especially true for iopromide, since some people react in a way that can create bigger problems than the original issue.
Certain groups run a higher chance of developing trouble after getting iopromide. Take someone with a known allergy to iodinated contrast agents. Their immune system responds wildly and can lead to hives, trouble breathing, or even shock—situations that put life at risk. It’s tempting to hope modern medicine always has an antidote, but allergic reactions unfold fast and don’t play fair. Always ask about allergies before even thinking about iopromide.
People with poor kidney function face another big concern. I saw this play out during my own time working alongside nephrologists. Iopromide gets filtered through the kidneys, so anyone with chronic kidney disease might notice real harm. Introducing an extra challenge to fragile kidneys sometimes sends a patient from the imaging suite straight to dialysis. That’s not a dramatic exaggeration. Research from The Journal of the American Society of Nephrology and similar sources points toward a connection between these types of agents and acute kidney injury, especially for people already at risk.
Thyroid disease also shapes decision-making around iopromide. Some patients, especially those with an overactive thyroid, could see a sudden spike in hormone production after exposure to iodine. I remember a case where a person with undiagnosed hyperthyroidism landed in the emergency room after a scan, heart racing and blood pressure rocketing upward. Reports in medical literature confirm that iopromide and similar agents occasionally trigger thyrotoxic crisis in susceptible individuals.
People with heart problems sometimes face challenges as well. Those with heart failure or severely reduced heart function might find it hard to cope with rapid changes in blood volume from the contrast agent. None of this means every scan ends in disaster, but these risks demand attention and respect.
Good care hinges on a simple idea: get the whole story before acting. Nobody likes paperwork, but taking an extra few minutes to listen to someone’s medical history can make all the difference. Many complications get avoided when doctors, nurses, and techs ask questions about prior reactions, kidney disease, and thyroid conditions. Not every patient remembers technical names, so it helps to dig a little deeper—has this person reacted badly to scans before, do they have trouble with their kidneys, or do they take thyroid medication?
Education and teamwork stand out as real solutions. Hospitals now use checklists and electronic flags to catch contraindications early. Plus, alternative imaging strategies, like non-contrast scans or MRI, often give clear answers without iopromide’s risks. Newer contrast agents sometimes boast safer track records, so keeping options open leads to better outcomes for everyone.
Doctors want clear pictures without causing new problems. Contraindications aren’t there to slow down progress—each warning tells a story written with patient safety in mind. Respecting those stories and adapting plans for each individual shapes better, safer health care. Every decision counts.
Iopromide shows up in radiology departments everywhere, helping doctors see better images during CT scans and angiograms. Radiologists rely on it because it makes blood vessels or organs stand out. Patients with healthy kidneys rarely face trouble from this contrast dye. For people with kidney challenges, though, questions and worries pile up quickly.
Some patients run into trouble after getting iopromide. What doctors call “contrast-induced nephropathy” or “contrast-induced acute kidney injury” can sneak up if kidneys start off struggling. Studies link contrast dyes—like iopromide—to a drop in kidney function for some patients, especially those with diabetes, dehydration, or long-standing kidney disease. In these cases, markers like creatinine can spike within 2-3 days after the scan. For someone facing this risk, every scan feels like a gamble.
Skipping diagnostic scans means missing out on answers. Doctors order these images because something serious might be brewing—blockages, tumors, and dangerous infections do not wait for perfect kidney numbers. Without the right scan, doctors have less information. Sometimes, lives hang in the balance—so for many, avoidance isn’t a safe option.
No easy answer fits all patients, but a careful plan can shrink the danger. Hydration stands out as a simple, evidence-backed approach. Fluids before and after the procedure help the kidneys flush out the dye. One of my loved ones faced a CT scan with already-compromised kidneys. The team set up an IV drip, checked bloodwork before and after, and used the lowest dye dose they could. The scan found a problem in time, and the kidneys recovered.
Doctors also take stock of kidney function using estimated GFR numbers and creatinine from recent lab work. If numbers look poor, alternative imaging like MRI or ultrasound comes into play. Sometimes, if the test just can’t wait, medical teams prepare with extra hydration and medications like N-acetylcysteine, though evidence around these helpers isn’t rock solid.
Over the years, research explored low-osmolar contrast agents like iopromide. Compared to older, high-osmolar dyes, iopromide causes fewer side effects and shows lower risk in healthy patients. For those already battling kidney challenges, risk still exists, just in a more manageable form. Guidelines from nephrology and radiology groups suggest using the minimum dose, making decisions case-by-case, and keeping a close watch on the patient’s condition before and after the scan.
Medical teams use software that tracks kidney function over time and flags risk quickly. Electronic alerts, chart reminders, and standardized protocols make it harder to miss these red flags. Still, the best safety net combines skilled doctors, up-to-date science, and clear information for the patient. Conversations matter—patients get a chance to weigh risks, ask questions, and plan for safe testing.
Safer contrasts are under review, and more studies keep refining what works. Until then, hospitals treat every kidney-compromised person as unique. By respecting the risk, staying well-hydrated, using smart protocols, and double-checking need for contrast, doctors protect kidney health while still chasing important answers from those scans.
| Names | |
| Preferred IUPAC name | N,N-Bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-(2-methoxyacetamido)-N-methylisophthalamide |
| Other names |
Ultravist |
| Pronunciation | /aɪˈɒprəmaɪd/ |
| Identifiers | |
| CAS Number | 73334-07-3 |
| Beilstein Reference | 1638052 |
| ChEBI | CHEBI:31638 |
| ChEMBL | CHEMBL1200706 |
| ChemSpider | 15986 |
| DrugBank | DB08808 |
| ECHA InfoCard | 100.111.143 |
| EC Number | EC 260-969-9 |
| Gmelin Reference | 1062439 |
| KEGG | D04738 |
| MeSH | D002110 |
| PubChem CID | 3730 |
| RTECS number | UW8580000 |
| UNII | QZC7KY7M3T |
| UN number | UN9262 |
| CompTox Dashboard (EPA) | DTXSID0022851 |
| Properties | |
| Chemical formula | C18H24I3N3O8 |
| Molar mass | 791.12 g/mol |
| Appearance | A clear, colorless to slightly yellow solution. |
| Odor | Odorless |
| Density | 1.33 g/cm³ |
| Solubility in water | freely soluble |
| log P | -1.4 |
| Vapor pressure | Negligible |
| Acidity (pKa) | pKa = 2.6 |
| Basicity (pKb) | 6.92 |
| Magnetic susceptibility (χ) | -59.0e-6 cm³/mol |
| Refractive index (nD) | 1.442 |
| Viscosity | 17.7 mPa·s |
| Dipole moment | 5.51 D |
| Pharmacology | |
| ATC code | V08AB05 |
| Hazards | |
| Main hazards | May cause allergic reactions, including anaphylaxis; risk of nephrotoxicity; can cause nausea, vomiting, and cardiovascular effects. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHS07, GHS08 |
| Signal word | Warning |
| Hazard statements | Hazard statements: Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008. |
| Precautionary statements | P201, P202, P280, P308+P313, P405, P501 |
| NFPA 704 (fire diamond) | 1-1-0 |
| Flash point | No flash point |
| Lethal dose or concentration | LD50 (rat, intravenous): 21.6 g/kg |
| LD50 (median dose) | LD50 (median dose): 21 g/kg (mouse, intravenous) |
| PEL (Permissible) | Not established |
| REL (Recommended) | 300–350 mg Iodine/mL |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Iohexol Iopamidol Ioversol Iodixanol |
